PDCD1 and neoplasm: The efficacy of anti-PD-1/PD-L1 treatments, while promising, remains suboptimal, hindered by various factors such as PD-L1 expression levels in the tumor microenvironment, lymphocyte infiltration, T-cell receptor clonality, tumor neoantigens, and peripheral blood markers.